July 30, 2018 – By Jason Dias
Headinvest Llc increased its stake in Fiserv (FISV) by 94.67% based on its latest 2018Q1 regulatory filing with the SEC. Headinvest Llc bought 48,172 shares as the company’s stock declined 1.25% with the market. The institutional investor held 99,054 shares of the technology company at the end of 2018Q1, valued at $7.06 million, up from 50,882 at the end of the previous reported quarter. Headinvest Llc who had been investing in Fiserv for a number of months, seems to be bullish on the $30.52 billion market cap company. The stock decreased 2.06% or $1.57 during the last trading session, reaching $74.55. About 1.02M shares traded. Fiserv, Inc. (NASDAQ:FISV) has risen 15.27% since July 30, 2017 and is uptrending. It has outperformed by 2.70% the S&P500.
Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 5.09% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 386,100 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 7.20M shares of the health care company at the end of 2018Q1, valued at $97.94M, down from 7.59 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $551.96M market cap company. The stock decreased 1.23% or $0.14 during the last trading session, reaching $11.23. About 106,849 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Among 24 analysts covering Fiserv (NASDAQ:FISV), 10 have Buy rating, 1 Sell and 13 Hold. Therefore 42% are positive. Fiserv had 61 analyst reports since July 30, 2015 according to SRatingsIntel. BMO Capital Markets maintained Fiserv, Inc. (NASDAQ:FISV) rating on Thursday, February 8. BMO Capital Markets has “Market Perform” rating and $152 target. The firm has “Neutral” rating by Citigroup given on Wednesday, May 2. Stephens maintained Fiserv, Inc. (NASDAQ:FISV) on Monday, February 5 with “Hold” rating. The rating was upgraded by Argus Research on Monday, May 9 to “Buy”. The firm has “Sell” rating by Compass Point given on Friday, April 15. The stock has “Neutral” rating by Credit Suisse on Wednesday, May 2. The stock of Fiserv, Inc. (NASDAQ:FISV) has “Buy” rating given on Wednesday, October 11 by Jefferies. The firm has “Hold” rating by SunTrust given on Tuesday, October 31. The firm earned “Equal Weight” rating on Thursday, July 30 by Barclays Capital. Robert W. Baird maintained Fiserv, Inc. (NASDAQ:FISV) on Wednesday, September 6 with “Buy” rating.
Since February 16, 2018, it had 1 buy, and 7 selling transactions for $19.83 million activity. DiSimone Harry had bought 353 shares worth $49,981. The insider ROBAK KIM M sold 10,388 shares worth $757,493. 50,000 shares were sold by YABUKI JEFFERY W, worth $3.85M.
Investors sentiment increased to 10.53 in Q1 2018. Its up 9.72, from 0.81 in 2017Q4. It is positive, as 39 investors sold FISV shares while 21 reduced holdings. 70 funds opened positions while 562 raised stakes. 700.79 million shares or 293.94% more from 177.89 million shares in 2017Q4 were reported. Los Angeles Cap Mngmt & Equity Research Inc has 221,416 shares for 0.09% of their portfolio. Exxonmobil Invest Tx invested in 0.13% or 63,260 shares. Morgan Stanley has invested 0.02% in Fiserv, Inc. (NASDAQ:FISV). Moreover, San Francisco Sentry Investment Group (Ca) has 0.01% invested in Fiserv, Inc. (NASDAQ:FISV) for 424 shares. National Bank Of Montreal Can holds 746,738 shares. Sva Plumb Wealth Management Ltd Llc, a Wisconsin-based fund reported 54,480 shares. Montag A & Associates owns 127,152 shares for 0.93% of their portfolio. Thompson Siegel Walmsley Lc has 1,896 shares. Cibc Asset Mngmt owns 183,662 shares. Louisiana State Employees Retirement reported 25,200 shares. Bailard Incorporated holds 0.1% or 21,200 shares in its portfolio. Moreover, Cullinan Assoc has 0.38% invested in Fiserv, Inc. (NASDAQ:FISV). Homrich Berg owns 0.03% invested in Fiserv, Inc. (NASDAQ:FISV) for 6,492 shares. Addenda owns 20,438 shares. New York State Common Retirement Fund accumulated 1.11M shares or 0.1% of the stock.
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Td Asset Mngmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Credit Suisse Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bogle Invest Management Lp De reported 21,104 shares. Smith Asset Management Group Lp holds 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 26,447 shares. New York State Common Retirement Fund, a New York-based fund reported 37,100 shares. Moreover, Franklin Res has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Management Limited Co invested in 0.02% or 79,000 shares. Nantahala Capital Management Limited Liability Co owns 600,488 shares. Element Cap Ltd Liability Corp, New York-based fund reported 14,453 shares. Millennium Management Limited Liability invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). 259,558 are owned by Geode Mgmt Ltd Com. Panagora Asset Mngmt holds 0.02% or 369,959 shares. Citadel Advsrs Limited has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein Ltd Partnership reported 40,100 shares stake. Strs Ohio accumulated 55,500 shares.
Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. ChemoCentryx had 9 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Sell” on Thursday, September 3. Cowen & Co maintained ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, August 8 with “Hold” rating. The firm has “Buy” rating given on Thursday, August 10 by JMP Securities. The stock has “Sell” rating by Zacks on Monday, September 21. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan. JMP Securities initiated the stock with “Mkt Outperform” rating in Tuesday, February 21 report.
Since May 1, 2018, it had 0 insider purchases, and 12 sales for $7.89 million activity. Schall Thomas J. had sold 50,000 shares worth $550,858 on Tuesday, May 1. On Wednesday, May 2 KANAYA SUSAN M sold $15,709 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 1,366 shares.
Bvf Inc, which manages about $999.89 million and $986.48 million US Long portfolio, upped its stake in Corvus Pharmaceuticals Inc by 1.49M shares to 1.95M shares, valued at $22.53 million in 2018Q1, according to the filing. It also increased its holding in Pieris Pharmaceuticals Inc by 968,987 shares in the quarter, for a total of 3.59M shares, and has risen its stake in Verastem Inc (NASDAQ:VSTM).
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 14. They expect $-0.11 EPS, up 42.11% or $0.08 from last year’s $-0.19 per share. After $-0.19 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -42.11% EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.